List view / Grid view
Porosome Therapeutics have announced new advancements in Alzheimer’s treatment – presenting therapies that restore neuronal function, reduce Tau protein levels and reverse disease pathology in human brain organoids.
Can a cholesterol enzyme help treat an untreatable liver disease? Esperion’s ACLY programme is using multiomic and preclinical data to evaluate its potential in primary sclerosing cholangitis.
Effective financial management is vital for clinical trial success, yet many preclinical and clinical companies face inefficiencies due to outdated systems. Jennifer Kyle, CEO of Condor Software, explains how advanced financial platforms can streamline processes, improve forecasting and ensure better resource allocation throughout drug development.
29 July 2025 | By Eurofins Discovery
Facing roadblocks in obesity drug discovery? Discover how integrated, validated strategies are helping teams accelerate development and reduce risk.
Researchers in Brazil and Poland have developed an AI-powered tool that predicts cancer aggressiveness by analysing protein expression - offering new insights into tumour behaviour.
Paris-based One Biosciences, a precision oncology biotech company, has raised €15 million in Series A financing to accelerate the development of its AI-powered single-cell tumour profiling platform.
Why do so many drug candidates fail before reaching patients – and can AI help stop the losses? In Part 2, Layla Hosseini-Gerami of Ignota Labs outlines the scope of the toxicity problem and explains why failures often come too late to fix.
New therapeutic approaches are emerging for CNS disorders – but can they overcome the toughest barriers in drug development? Find out what is driving progress and what still stands in the way.
Why do so many drug candidates fail before reaching patients – and can AI help stop the losses? In Part 1, Layla Hosseini-Gerami of Ignota Labs outlines the scope of the toxicity problem and explains why failures often come too late to fix.
Single-cell and spatial technologies are giving researchers an unprecedented view of how brain diseases like Alzheimer’s really work. The result? Faster discovery, clearer targets and a new path towards more effective treatments.
AI will not replace drug discovery, but it might finally fix one of its most frustrating bottlenecks. Read how a targeted approach to ADMET is cutting through the noise.
Shift Bioscience has published a new study introducing enhanced metrics and baselines for evaluating virtual cell models - boosting gene target discovery and accelerating its rejuvenation therapeutics pipeline.
Want to understand the real impact of AI in 3D sample analysis? This episode cuts straight to how machine learning is accelerating research and overcoming current limitations.
Using GenAI and expert reasoning, drug developers can now explore an asset’s long-term potential as early as the preclinical stage. This shift is helping to reshape pipeline planning and refine therapeutic strategy.
AI is changing how clinical trials are run - quietly but significantly. Find out how digital twins are helping sponsors reduce control arms and accelerate development without changing trial endpoints.
